NewLimit closed a $45 million financing round that included investments from Lilly Ventures and S32, positioning the company to advance its anti‑aging programs. The startup, cofounded by entrepreneurs with high‑profile ties, said the funds will accelerate preclinical and translational work aimed at longevity interventions. NewLimit framed the round as validation from strategic life‑science investors and intends to use proceeds to scale discovery efforts and prepare candidates for clinical development. The funding highlights continued venture interest in aging biology and companies pursuing translational paths to extend healthspan.